Blog Category

NSAIDs: More Bad News 
Posted on May 15, 2017

  NSAIDs are an $11-12+ billion market, yet the problems with these drugs continue to make headlines.  The most recent study examined data from nearly 450,000 patients, and concluded (our emphasis):  All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was

Control or Collaboration – Value Creation & Success Focus 
Posted on May 12, 2017

  The following commentary is from Mr. Tom Brya, Managing Director at Titenare GXL. Titenare is an international consultancy providing integrated, knowledge-based services and  solutions to pharma companies internationally. For further information, please visit The pharma business model is rapidly moving towards a PwC 2009 prediction, which said that the industry will become collaboration-centric. This was

Biosimilars: Who wants to play this game? 
Posted on Apr 14, 2017

     A recent post by Robert Wessman of Alvogen pointed out that some companies are abandoning their efforts in the biosimilars markets. Amgen, for instance, recently decided to postpone the launch of a biosimilar version of adalimumab until litigation issues are resolved, which could take years (if ever). By the way, adalimumab is a

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.